Analysis of the efficacy of oral immunotherapy combined with Lactobacillus rhamnosus GG for patients with food allergy

Analysis of the efficacy of oral immunotherapy combined with Lactobacillus rhamnosus GG for patients with food allergy - Analysis of the efficacy of oral immunotherapy combined with Lactobacillus rhamnosus GG for patients with food allergy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037482

Enrollment

Registered

2019-07-25

Start date

2019-07-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

food allergy

Interventions

Patients consume Lactobacillus rhamnosus GG during the oral immunotherapy for 1 year.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who reacted to low-dose oral food challenge. Low-dose was defined as 'one eighth of the whole egg, 3 ml of cow's milk, 2 g of udon noodle (Japanese wheat noodle), 0.5 g of whole peanuts, or 0.5 g of nuts.'

Exclusion criteria

Exclusion criteria: Decision of ineligibility by a physician

Design outcomes

Primary

Measure	Time frame
Sustained unresponsiveness to middle dose after 12 months. Middle dose was defined as half of the whole egg, 25ml of cow's milk, 25g of udon noodle (Japanese wheat noodle), 3g of peanuts, or 3g of nuts.	—

Secondary

Measure	Time frame
Intestinal microbiota Short-chain fatty acids (acetic acid, butyric acid, propionic acid, valeric acid) in the serum Changes in specific IgE, IgG, and IgG4 titer Frequency of adverse reactions during therapy	—

Countries

Japan

Contacts

Public ContactYoko Miura

National Hospital Organization Sagamihara National Hospital Pediatrics

yoko6299@gmail.com042-742-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026